Daxor Corporation (DXR) 10-Year Financial Performance & Capital Metrics

DXR • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

AboutDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.Show more

Revenue $2M -93.8%
EBITDA $2M +146.0%
Net Income $536K +91.1%
EPS (Diluted) 0.11 +81.5%
Gross Margin 100% +0.5%
EBITDA Margin 96.59% +3893.8%
Operating Margin 29.16% +2959.1%
Net Margin 25.17% +3002.4%
ROE 1.54% +72.4%
ROIC 1.31% +71.7%
Debt/Equity 0.02 -8.2%
Interest Coverage 7.30 +8.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM86.61%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-51.66%

TTM-58.7%

EPS CAGR

10Y-

5Y-

3Y-54.66%

TTM-18.04%

ROCE

10Y Avg0.29%

5Y Avg6.85%

3Y Avg7.36%

Latest1.74%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.52B	34.59	617.68	21.95%	31.03%	29.08%	0.14%
DXRDaxor Corporation	69.03M	13.70	124.55	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	59.36B	208.35	35.74	8.23%	7.68%	6.61%	4.5%	0.76
HOLXHologic, Inc.	16.73B	75.02	22.60	-0%	13.79%	11.5%	6.84%	0.52
GCTKGlucoTrack, Inc.	3.62M	3.98	0.07			-389.1%
QDELQuidelOrtho Corporation	2.4B	35.38	-1.16	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.34B	22.98	-4.48	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	196.55M	2.74	-10.54	-54.17%	-47.92%	-16.64%	12%	0.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	-7.44M	1.84M	-1.01M	-918.45K	-114.99K	-2.81M	-2.62M	-353.36K	34.59M	2.13M
Revenue Growth %	-0.84%	1.25%	-1.55%	0.09%	0.87%	-23.4%	0.07%	0.86%	98.89%	-0.94%
Cost of Goods Sold+	314.85K	276.75K	200.08K	268.48K	367.17K	686.42K	1M	1.09M	177.07K	0
COGS % of Revenue	-0.04%	0.15%	-0.2%	-0.29%	-3.19%	-0.24%	-0.38%	-3.08%	0.01%	-
Gross Profit+	-7.76M	1.56M	-1.21M	-1.19M	-482.16K	-3.49M	-3.62M	-1.44M	34.41M	2.13M
Gross Margin %	1.04%	0.85%	1.2%	1.29%	4.19%	1.24%	1.38%	4.08%	0.99%	1%
Gross Profit Growth %	-0.91%	1.2%	-1.78%	0.02%	0.59%	-6.24%	-0.04%	0.6%	24.89%	-0.94%
Operating Expenses+	436.82K	367.95K	203.69K	299.88K	380.7K	734.37K	1.07M	1.09M	939.06K	1.59M
OpEx % of Revenue	-0.06%	0.2%	-0.2%	-0.33%	-3.31%	-0.26%	-0.41%	-3.07%	0.03%	0.75%
Selling, General & Admin	378.09K	304.87K	124.6K	256.76K	384.18K	593.52K	991.31K	1.09M	307.36K	294.19K
SG&A % of Revenue	-0.05%	0.17%	-0.12%	-0.28%	-3.34%	-0.21%	-0.38%	-3.07%	0.01%	0.14%
Research & Development	0	0	0	0	0	0	0	-15	0	0
R&D % of Revenue	-	-	-	-	-	-	-	0%	-	-
Other Operating Expenses	58.73K	63.08K	79.09K	43.12K	-3.48K	140.85K	81.68K	15	631.7K	1.3M
Operating Income+	-7.88M	1.47M	-1.14M	-1.1M	-495.7K	-1.73M	4.75M	5.25M	329.74K	621.42K
Operating Margin %	1.06%	0.8%	1.13%	1.19%	4.31%	0.62%	-1.82%	-14.86%	0.01%	0.29%
Operating Income Growth %	-0.75%	1.19%	-1.78%	0.04%	0.55%	-2.49%	3.74%	0.11%	-0.94%	0.88%
EBITDA+	-7.72M	1.24M	-1.57M	-1.27M	-517.14K	-1.72M	5.49M	6.11M	836.56K	2.06M
EBITDA Margin %	1.04%	0.67%	1.55%	1.38%	4.5%	0.61%	-2.1%	-17.29%	0.02%	0.97%
EBITDA Growth %	-0.81%	1.16%	-2.27%	0.19%	0.59%	-2.33%	4.19%	0.11%	-0.86%	1.46%
D&A (Non-Cash Add-back)	160.65K	-228.75K	-426.82K	-173.2K	-21.44K	0	745.58K	859.73K	506.81K	1.44M
EBIT	-7.88M	1.47M	-3.01M	-1.22M	-495.7K	-1.72M	4.77M	5.25M	329.74K	621.42K
Net Interest Income+	-160.65K	-37.33K	-72.97K	-121.25K	-143.49K	-8.4K	-19.61K	-72.45K	-49.1K	-85.09K
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	160.65K	37.33K	72.97K	121.25K	143.49K	8.4K	19.61K	72.45K	49.1K	85.09K
Other Income/Expense	0	0	649.55K	-854.56K	0	-8.4K	-19.61K	-72.45K	-49.1K	-85.09K
Pretax Income+	-7.88M	1.47M	-1.22M	-1.22M	-495.7K	-1.73M	4.75M	5.18M	280.64K	536.33K
Pretax Margin %	1.06%	0.8%	1.2%	1.33%	4.31%	0.62%	-1.82%	-14.65%	0.01%	0.25%
Income Tax+	1.27M	11.61K	24.61K	-332.55K	0	-25.28K	0	0	0	0
Effective Tax Rate %	1.16%	0.99%	1.02%	0.73%	1%	0.99%	1%	1%	1%	1%
Net Income+	-9.15M	1.46M	-1.24M	-885.77K	-495.7K	-1.71M	4.75M	5.18M	280.64K	536.33K
Net Margin %	1.23%	0.79%	1.23%	0.96%	4.31%	0.61%	-1.82%	-14.65%	0.01%	0.25%
Net Income Growth %	-8.36%	1.16%	-1.85%	0.29%	0.44%	-2.44%	3.78%	0.09%	-0.95%	0.91%
Net Income (Continuing)	-9.15M	1.46M	-1.24M	-885.77K	-495.7K	-1.71M	4.75M	5.18M	280.64K	536.33K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.38	0.33	-0.33	-0.24	-0.12	-0.43	1.18	0.60	0.06	0.11
EPS Growth %	-8.15%	1.14%	-2%	0.27%	0.5%	-2.58%	3.74%	-0.49%	-0.9%	0.82%
EPS (Basic)	-2.38	0.33	-0.33	-0.24	-0.12	-0.43	1.18	0.60	0.06	0.11
Diluted Shares Outstanding	3.84M	3.83M	3.77M	3.74M	4.19M	3.94M	4.04M	8.58M	4.63M	4.84M
Basic Shares Outstanding	3.84M	3.8M	3.74M	3.74M	4.19M	3.94M	4.04M	8.58M	4.63M	4.84M
Dividend Payout Ratio	-	0.08%	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.49M	2.62M	45.27K	36.72K	32.74K	0	764.5K	37.84K	25.88K	18.57K
Cash & Short-Term Investments	2.46M	2.18M	1.09M	0	0	617.8K	710.7K	0	0	0
Cash Only	2.46M	2.18M	1.09M	0	0	617.8K	710.7K	0	0	0
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	33.38K	45.87K	45.27K	33.71K	32.74K	29.3K	30.7K	17.23K	14.2K	9.68K
Days Sales Outstanding	-1.64	9.12	-16.33	-13.4	-103.91	-3.81	-4.28	-17.8	0.15	1.66
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2.46M	2.57M	1.09M	357K	0	-647.1K	0	0	0	8.89K
Total Non-Current Assets+	18.38M	17.97M	18.14M	17.24M	13.97M	15.67M	24.22M	30.22M	34.84M	36.61M
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	18.38M	17.97M	18.14M	17.24M	13.97M	15.67M	24.22M	30.22M	34.84M	36.61M
Other Non-Current Assets	-18.38M	-17.97M	-18.14M	-17.24M	0	0	0	0	0	0
Total Assets+	20.89M	20.62M	19.31M	17.63M	14.2M	16.55M	24.98M	30.26M	34.87M	36.63M
Asset Turnover	-0.36x	0.09x	-0.05x	-0.05x	-0.01x	-0.17x	-0.10x	-0.01x	0.99x	0.06x
Asset Growth %	-0.55%	-0.01%	-0.06%	-0.09%	-0.19%	0.17%	0.51%	0.21%	0.15%	0.05%
Total Current Liabilities+	9.14K	7.82K	75K	72.5K	78.75K	707K	806.42K	62.44K	103.1K	110.33K
Accounts Payable	9.14K	7.82K	75K	72.5K	78.75K	80K	87.4K	62.44K	103.1K	110.33K
Days Payables Outstanding	10.59	10.31	136.82	98.56	78.29	42.54	31.85	20.96	212.52	-
Short-Term Debt	0	0	0	0	0	627K	715.8K	0	0	0
Deferred Revenue (Current)	-1000K	-1000K	-1000K	0	0	0	0	0	0	0
Other Current Liabilities	-9.14K	-7.82K	-75K	-72.5K	0	0	3.23K	0	0	0
Current Ratio	272.35x	335.00x	0.60x	0.51x	0.42x	-	0.95x	0.61x	0.25x	0.17x
Quick Ratio	272.35x	335.00x	0.60x	0.51x	0.42x	-	0.95x	0.61x	0.25x	0.17x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.85M	2.8M	4.33M	4.45M	1.34M	170.69K	3.02M	1.23M	755.66K	729.97K
Long-Term Debt	3.85M	2.8M	4.33M	4.45M	1.34M	170.69K	3.02M	1.23M	755.66K	729.97K
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-3.85M	-2.8M	-4.33M	-4.45M	0	0	0	0	0	0
Total Liabilities	6.47M	5.28M	5.55M	4.56M	1.44M	877.69K	3.83M	1.29M	858.76K	840.3K
Total Debt+	3.85M	2.8M	4.33M	4.45M	1.34M	170.69K	3.02M	1.23M	755.66K	729.97K
Net Debt	1.39M	617.87K	3.25M	4.45M	1.34M	-447.11K	2.31M	1.23M	755.66K	729.97K
Debt / Equity	0.27x	0.18x	0.32x	0.34x	0.11x	0.01x	0.14x	0.04x	0.02x	0.02x
Debt / EBITDA	-	2.26x	-	-	-	-	0.55x	0.20x	0.90x	0.35x
Net Debt / EBITDA	-	0.50x	-	-	-	-	0.42x	0.20x	0.90x	0.35x
Interest Coverage	-49.06x	39.31x	-15.65x	-9.05x	-3.45x	-205.98x	242.19x	72.47x	6.72x	7.30x
Total Equity+	14.43M	15.34M	13.76M	13.06M	12.77M	15.68M	21.15M	28.97M	34.01M	35.79M
Equity Growth %	-0.41%	0.06%	-0.1%	-0.05%	-0.02%	0.23%	0.35%	0.37%	0.17%	0.05%
Book Value per Share	3.75	4.01	3.65	3.49	3.05	3.98	5.24	3.38	7.34	7.39
Total Shareholders' Equity	14.43M	15.34M	13.76M	13.06M	12.77M	15.68M	21.15M	28.97M	34.01M	35.79M
Common Stock	10.75M	53.17K	53.17K	53.17K	53.17K	53.17K	53.17K	53.17K	53.17K	54.09K
Retained Earnings	10.24M	10.38M	8.48M	17.06M	16.57M	14.86M	19.61M	24.79M	25.09M	25.63M
Treasury Stock	-14.28M	-14.72M	-14.97M	-14.86M	-14.86M	-10.62M	-10.62M	-8.77M	-4.83M	-4.5M
Accumulated OCI	0	0	0	17.06M	16.57M	14.86M	19.61M	24.79M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	18.53M	1.59M	-1.17M	-1.32M	3.11M	-2.45M	-2.76M	-769.3K	-3.66M	25.69K
Operating CF Margin %	-2.49%	0.87%	1.16%	1.43%	-27.06%	0.87%	1.05%	2.18%	-0.11%	0.01%
Operating CF Growth %	63.66%	-0.91%	-1.74%	-0.12%	3.37%	-1.79%	-0.13%	0.72%	-3.75%	1.01%
Net Income	-9.15M	1.46M	-1.24M	-885.77K	-495.7K	-1.71M	4.75M	5.18M	280.64K	536.33K
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	7.54K	10.32K	13.51K	83.83K	199.36K	377.61K	729.34K	786.64K	631.7K	0
Deferred Taxes	1.22M	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	27.4M	273.29K	-1.47M	-91.36K	3.24M	-1.09M	-8.45M	-6.73M	-4.62M	-524.73K
Working Capital Changes	275.17K	-136.36K	1.54M	-338.48K	165.75K	-30.73K	216.79K	-9.01K	52.62K	14.09K
Change in Receivables	100.51K	-401.76K	389.87K	-345.44K	3.99K	3.44K	-1.4K	13.47K	3.04K	4.52K
Change in Inventory	0	0	0	0	0	0	0	22.47K	0	0
Change in Payables	-6.76K	-1.32K	61.5K	-2.5K	6.25K	1.25K	7.4K	-22.47K	40.66K	-8.6K
Cash from Investing+	2.45M	0	0	0	5.19M	367.93K	74.76K	2.69M	2.75M	1.94M
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-0%	-0%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	-18.53M	-1.59M	1.17M	226.39K	-3.11M	3.07M	2.85M	58.6K	3.66M	-25.69K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-154.1K	-113.99K	-112.1K	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	201.19K	0	0	-401.27K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	18.53M	1.59M	-1.17M	-1.32M	3.11M	-2.45M	-2.76M	-769.3K	-3.66M	25.69K
FCF Margin %	-2.49%	0.87%	1.16%	1.43%	-27.06%	0.87%	1.05%	2.18%	-0.11%	0.01%
FCF Growth %	63.66%	-0.91%	-1.74%	-0.12%	3.37%	-1.79%	-0.13%	0.72%	-3.75%	1.01%
FCF per Share	4.82	0.42	-0.31	-0.35	0.74	-0.62	-0.68	-0.09	-0.79	0.01
FCF Conversion (FCF/Net Income)	-2.03x	1.09x	0.95x	1.49x	-6.28x	1.44x	-0.58x	-0.15x	-13.02x	0.05x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.89%	9.78%	-8.52%	-6.61%	-3.84%	-11.99%	25.79%	20.66%	0.89%	1.54%
Return on Invested Capital (ROIC)	-19.14%	6.93%	-5.2%	-4.77%	-2.35%	-8.85%	18.41%	14.68%	0.76%	1.31%
Gross Margin	104.23%	84.92%	119.78%	129.23%	419.3%	124.46%	138.3%	407.64%	99.49%	100%
Net Margin	122.87%	79.32%	122.57%	96.44%	431.07%	60.77%	-181.56%	-1465.41%	0.81%	25.17%
Debt / Equity	0.27x	0.18x	0.32x	0.34x	0.11x	0.01x	0.14x	0.04x	0.02x	0.02x
Interest Coverage	-49.06x	39.31x	-15.65x	-9.05x	-3.45x	-205.98x	242.19x	72.47x	6.72x	7.30x
FCF Conversion	-2.03x	1.09x	0.95x	1.49x	-6.28x	1.44x	-0.58x	-0.15x	-13.02x	0.05x
Revenue Growth	-83.63%	124.66%	-155.12%	9.21%	87.48%	-2340.47%	6.81%	86.49%	9889.04%	-93.84%

Frequently Asked Questions

Valuation & Price

Daxor Corporation (DXR) has a price-to-earnings (P/E) ratio of 124.5x. This suggests investors expect higher future growth.

Growth & Financials

Daxor Corporation (DXR) reported $0.9M in revenue for fiscal year 2024. This represents a 32% decrease from $1.3M in 2011.

Daxor Corporation (DXR) saw revenue decline by 93.8% over the past year.

Yes, Daxor Corporation (DXR) is profitable, generating $3.5M in net income for fiscal year 2024 (25.2% net margin).

Dividend & Returns

Daxor Corporation (DXR) has a return on equity (ROE) of 1.5%. This is below average, suggesting room for improvement.

Daxor Corporation (DXR) had negative free cash flow of $4.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Daxor Corporation (DXR) 10-Year Financial Performance & Capital Metrics

DXR • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

Revenue $2M -93.8%
EBITDA $2M +146.0%
Net Income $536K +91.1%
EPS (Diluted) 0.11 +81.5%
Gross Margin 100% +0.5%
EBITDA Margin 96.59% +3893.8%
Operating Margin 29.16% +2959.1%
Net Margin 25.17% +3002.4%
ROE 1.54% +72.4%
ROIC 1.31% +71.7%
Debt/Equity 0.02 -8.2%
Interest Coverage 7.30 +8.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM86.61%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-51.66%

TTM-58.7%

EPS CAGR

10Y-

5Y-

3Y-54.66%

TTM-18.04%

ROCE

10Y Avg0.29%

5Y Avg6.85%

3Y Avg7.36%

Latest1.74%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.52B	34.59	617.68	21.95%	31.03%	29.08%	0.14%
DXRDaxor Corporation	69.03M	13.70	124.55	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	59.36B	208.35	35.74	8.23%	7.68%	6.61%	4.5%	0.76
HOLXHologic, Inc.	16.73B	75.02	22.60	-0%	13.79%	11.5%	6.84%	0.52
GCTKGlucoTrack, Inc.	3.62M	3.98	0.07			-389.1%
QDELQuidelOrtho Corporation	2.4B	35.38	-1.16	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.34B	22.98	-4.48	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	196.55M	2.74	-10.54	-54.17%	-47.92%	-16.64%	12%	0.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	-7.44M	1.84M	-1.01M	-918.45K	-114.99K	-2.81M	-2.62M	-353.36K	34.59M	2.13M
Revenue Growth %	-0.84%	1.25%	-1.55%	0.09%	0.87%	-23.4%	0.07%	0.86%	98.89%	-0.94%
Cost of Goods Sold+	314.85K	276.75K	200.08K	268.48K	367.17K	686.42K	1M	1.09M	177.07K	0
COGS % of Revenue	-0.04%	0.15%	-0.2%	-0.29%	-3.19%	-0.24%	-0.38%	-3.08%	0.01%	-
Gross Profit+	-7.76M	1.56M	-1.21M	-1.19M	-482.16K	-3.49M	-3.62M	-1.44M	34.41M	2.13M
Gross Margin %	1.04%	0.85%	1.2%	1.29%	4.19%	1.24%	1.38%	4.08%	0.99%	1%
Gross Profit Growth %	-0.91%	1.2%	-1.78%	0.02%	0.59%	-6.24%	-0.04%	0.6%	24.89%	-0.94%
Operating Expenses+	436.82K	367.95K	203.69K	299.88K	380.7K	734.37K	1.07M	1.09M	939.06K	1.59M
OpEx % of Revenue	-0.06%	0.2%	-0.2%	-0.33%	-3.31%	-0.26%	-0.41%	-3.07%	0.03%	0.75%
Selling, General & Admin	378.09K	304.87K	124.6K	256.76K	384.18K	593.52K	991.31K	1.09M	307.36K	294.19K
SG&A % of Revenue	-0.05%	0.17%	-0.12%	-0.28%	-3.34%	-0.21%	-0.38%	-3.07%	0.01%	0.14%
Research & Development	0	0	0	0	0	0	0	-15	0	0
R&D % of Revenue	-	-	-	-	-	-	-	0%	-	-
Other Operating Expenses	58.73K	63.08K	79.09K	43.12K	-3.48K	140.85K	81.68K	15	631.7K	1.3M
Operating Income+	-7.88M	1.47M	-1.14M	-1.1M	-495.7K	-1.73M	4.75M	5.25M	329.74K	621.42K
Operating Margin %	1.06%	0.8%	1.13%	1.19%	4.31%	0.62%	-1.82%	-14.86%	0.01%	0.29%
Operating Income Growth %	-0.75%	1.19%	-1.78%	0.04%	0.55%	-2.49%	3.74%	0.11%	-0.94%	0.88%
EBITDA+	-7.72M	1.24M	-1.57M	-1.27M	-517.14K	-1.72M	5.49M	6.11M	836.56K	2.06M
EBITDA Margin %	1.04%	0.67%	1.55%	1.38%	4.5%	0.61%	-2.1%	-17.29%	0.02%	0.97%
EBITDA Growth %	-0.81%	1.16%	-2.27%	0.19%	0.59%	-2.33%	4.19%	0.11%	-0.86%	1.46%
D&A (Non-Cash Add-back)	160.65K	-228.75K	-426.82K	-173.2K	-21.44K	0	745.58K	859.73K	506.81K	1.44M
EBIT	-7.88M	1.47M	-3.01M	-1.22M	-495.7K	-1.72M	4.77M	5.25M	329.74K	621.42K
Net Interest Income+	-160.65K	-37.33K	-72.97K	-121.25K	-143.49K	-8.4K	-19.61K	-72.45K	-49.1K	-85.09K
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	160.65K	37.33K	72.97K	121.25K	143.49K	8.4K	19.61K	72.45K	49.1K	85.09K
Other Income/Expense	0	0	649.55K	-854.56K	0	-8.4K	-19.61K	-72.45K	-49.1K	-85.09K
Pretax Income+	-7.88M	1.47M	-1.22M	-1.22M	-495.7K	-1.73M	4.75M	5.18M	280.64K	536.33K
Pretax Margin %	1.06%	0.8%	1.2%	1.33%	4.31%	0.62%	-1.82%	-14.65%	0.01%	0.25%
Income Tax+	1.27M	11.61K	24.61K	-332.55K	0	-25.28K	0	0	0	0
Effective Tax Rate %	1.16%	0.99%	1.02%	0.73%	1%	0.99%	1%	1%	1%	1%
Net Income+	-9.15M	1.46M	-1.24M	-885.77K	-495.7K	-1.71M	4.75M	5.18M	280.64K	536.33K
Net Margin %	1.23%	0.79%	1.23%	0.96%	4.31%	0.61%	-1.82%	-14.65%	0.01%	0.25%
Net Income Growth %	-8.36%	1.16%	-1.85%	0.29%	0.44%	-2.44%	3.78%	0.09%	-0.95%	0.91%
Net Income (Continuing)	-9.15M	1.46M	-1.24M	-885.77K	-495.7K	-1.71M	4.75M	5.18M	280.64K	536.33K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.38	0.33	-0.33	-0.24	-0.12	-0.43	1.18	0.60	0.06	0.11
EPS Growth %	-8.15%	1.14%	-2%	0.27%	0.5%	-2.58%	3.74%	-0.49%	-0.9%	0.82%
EPS (Basic)	-2.38	0.33	-0.33	-0.24	-0.12	-0.43	1.18	0.60	0.06	0.11
Diluted Shares Outstanding	3.84M	3.83M	3.77M	3.74M	4.19M	3.94M	4.04M	8.58M	4.63M	4.84M
Basic Shares Outstanding	3.84M	3.8M	3.74M	3.74M	4.19M	3.94M	4.04M	8.58M	4.63M	4.84M
Dividend Payout Ratio	-	0.08%	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.49M	2.62M	45.27K	36.72K	32.74K	0	764.5K	37.84K	25.88K	18.57K
Cash & Short-Term Investments	2.46M	2.18M	1.09M	0	0	617.8K	710.7K	0	0	0
Cash Only	2.46M	2.18M	1.09M	0	0	617.8K	710.7K	0	0	0
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	33.38K	45.87K	45.27K	33.71K	32.74K	29.3K	30.7K	17.23K	14.2K	9.68K
Days Sales Outstanding	-1.64	9.12	-16.33	-13.4	-103.91	-3.81	-4.28	-17.8	0.15	1.66
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2.46M	2.57M	1.09M	357K	0	-647.1K	0	0	0	8.89K
Total Non-Current Assets+	18.38M	17.97M	18.14M	17.24M	13.97M	15.67M	24.22M	30.22M	34.84M	36.61M
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	18.38M	17.97M	18.14M	17.24M	13.97M	15.67M	24.22M	30.22M	34.84M	36.61M
Other Non-Current Assets	-18.38M	-17.97M	-18.14M	-17.24M	0	0	0	0	0	0
Total Assets+	20.89M	20.62M	19.31M	17.63M	14.2M	16.55M	24.98M	30.26M	34.87M	36.63M
Asset Turnover	-0.36x	0.09x	-0.05x	-0.05x	-0.01x	-0.17x	-0.10x	-0.01x	0.99x	0.06x
Asset Growth %	-0.55%	-0.01%	-0.06%	-0.09%	-0.19%	0.17%	0.51%	0.21%	0.15%	0.05%
Total Current Liabilities+	9.14K	7.82K	75K	72.5K	78.75K	707K	806.42K	62.44K	103.1K	110.33K
Accounts Payable	9.14K	7.82K	75K	72.5K	78.75K	80K	87.4K	62.44K	103.1K	110.33K
Days Payables Outstanding	10.59	10.31	136.82	98.56	78.29	42.54	31.85	20.96	212.52	-
Short-Term Debt	0	0	0	0	0	627K	715.8K	0	0	0
Deferred Revenue (Current)	-1000K	-1000K	-1000K	0	0	0	0	0	0	0
Other Current Liabilities	-9.14K	-7.82K	-75K	-72.5K	0	0	3.23K	0	0	0
Current Ratio	272.35x	335.00x	0.60x	0.51x	0.42x	-	0.95x	0.61x	0.25x	0.17x
Quick Ratio	272.35x	335.00x	0.60x	0.51x	0.42x	-	0.95x	0.61x	0.25x	0.17x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.85M	2.8M	4.33M	4.45M	1.34M	170.69K	3.02M	1.23M	755.66K	729.97K
Long-Term Debt	3.85M	2.8M	4.33M	4.45M	1.34M	170.69K	3.02M	1.23M	755.66K	729.97K
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-3.85M	-2.8M	-4.33M	-4.45M	0	0	0	0	0	0
Total Liabilities	6.47M	5.28M	5.55M	4.56M	1.44M	877.69K	3.83M	1.29M	858.76K	840.3K
Total Debt+	3.85M	2.8M	4.33M	4.45M	1.34M	170.69K	3.02M	1.23M	755.66K	729.97K
Net Debt	1.39M	617.87K	3.25M	4.45M	1.34M	-447.11K	2.31M	1.23M	755.66K	729.97K
Debt / Equity	0.27x	0.18x	0.32x	0.34x	0.11x	0.01x	0.14x	0.04x	0.02x	0.02x
Debt / EBITDA	-	2.26x	-	-	-	-	0.55x	0.20x	0.90x	0.35x
Net Debt / EBITDA	-	0.50x	-	-	-	-	0.42x	0.20x	0.90x	0.35x
Interest Coverage	-49.06x	39.31x	-15.65x	-9.05x	-3.45x	-205.98x	242.19x	72.47x	6.72x	7.30x
Total Equity+	14.43M	15.34M	13.76M	13.06M	12.77M	15.68M	21.15M	28.97M	34.01M	35.79M
Equity Growth %	-0.41%	0.06%	-0.1%	-0.05%	-0.02%	0.23%	0.35%	0.37%	0.17%	0.05%
Book Value per Share	3.75	4.01	3.65	3.49	3.05	3.98	5.24	3.38	7.34	7.39
Total Shareholders' Equity	14.43M	15.34M	13.76M	13.06M	12.77M	15.68M	21.15M	28.97M	34.01M	35.79M
Common Stock	10.75M	53.17K	53.17K	53.17K	53.17K	53.17K	53.17K	53.17K	53.17K	54.09K
Retained Earnings	10.24M	10.38M	8.48M	17.06M	16.57M	14.86M	19.61M	24.79M	25.09M	25.63M
Treasury Stock	-14.28M	-14.72M	-14.97M	-14.86M	-14.86M	-10.62M	-10.62M	-8.77M	-4.83M	-4.5M
Accumulated OCI	0	0	0	17.06M	16.57M	14.86M	19.61M	24.79M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	18.53M	1.59M	-1.17M	-1.32M	3.11M	-2.45M	-2.76M	-769.3K	-3.66M	25.69K
Operating CF Margin %	-2.49%	0.87%	1.16%	1.43%	-27.06%	0.87%	1.05%	2.18%	-0.11%	0.01%
Operating CF Growth %	63.66%	-0.91%	-1.74%	-0.12%	3.37%	-1.79%	-0.13%	0.72%	-3.75%	1.01%
Net Income	-9.15M	1.46M	-1.24M	-885.77K	-495.7K	-1.71M	4.75M	5.18M	280.64K	536.33K
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	7.54K	10.32K	13.51K	83.83K	199.36K	377.61K	729.34K	786.64K	631.7K	0
Deferred Taxes	1.22M	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	27.4M	273.29K	-1.47M	-91.36K	3.24M	-1.09M	-8.45M	-6.73M	-4.62M	-524.73K
Working Capital Changes	275.17K	-136.36K	1.54M	-338.48K	165.75K	-30.73K	216.79K	-9.01K	52.62K	14.09K
Change in Receivables	100.51K	-401.76K	389.87K	-345.44K	3.99K	3.44K	-1.4K	13.47K	3.04K	4.52K
Change in Inventory	0	0	0	0	0	0	0	22.47K	0	0
Change in Payables	-6.76K	-1.32K	61.5K	-2.5K	6.25K	1.25K	7.4K	-22.47K	40.66K	-8.6K
Cash from Investing+	2.45M	0	0	0	5.19M	367.93K	74.76K	2.69M	2.75M	1.94M
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-0%	-0%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	-18.53M	-1.59M	1.17M	226.39K	-3.11M	3.07M	2.85M	58.6K	3.66M	-25.69K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-154.1K	-113.99K	-112.1K	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	201.19K	0	0	-401.27K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	18.53M	1.59M	-1.17M	-1.32M	3.11M	-2.45M	-2.76M	-769.3K	-3.66M	25.69K
FCF Margin %	-2.49%	0.87%	1.16%	1.43%	-27.06%	0.87%	1.05%	2.18%	-0.11%	0.01%
FCF Growth %	63.66%	-0.91%	-1.74%	-0.12%	3.37%	-1.79%	-0.13%	0.72%	-3.75%	1.01%
FCF per Share	4.82	0.42	-0.31	-0.35	0.74	-0.62	-0.68	-0.09	-0.79	0.01
FCF Conversion (FCF/Net Income)	-2.03x	1.09x	0.95x	1.49x	-6.28x	1.44x	-0.58x	-0.15x	-13.02x	0.05x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.89%	9.78%	-8.52%	-6.61%	-3.84%	-11.99%	25.79%	20.66%	0.89%	1.54%
Return on Invested Capital (ROIC)	-19.14%	6.93%	-5.2%	-4.77%	-2.35%	-8.85%	18.41%	14.68%	0.76%	1.31%
Gross Margin	104.23%	84.92%	119.78%	129.23%	419.3%	124.46%	138.3%	407.64%	99.49%	100%
Net Margin	122.87%	79.32%	122.57%	96.44%	431.07%	60.77%	-181.56%	-1465.41%	0.81%	25.17%
Debt / Equity	0.27x	0.18x	0.32x	0.34x	0.11x	0.01x	0.14x	0.04x	0.02x	0.02x
Interest Coverage	-49.06x	39.31x	-15.65x	-9.05x	-3.45x	-205.98x	242.19x	72.47x	6.72x	7.30x
FCF Conversion	-2.03x	1.09x	0.95x	1.49x	-6.28x	1.44x	-0.58x	-0.15x	-13.02x	0.05x
Revenue Growth	-83.63%	124.66%	-155.12%	9.21%	87.48%	-2340.47%	6.81%	86.49%	9889.04%	-93.84%

Frequently Asked Questions

Valuation & Price

Daxor Corporation (DXR) has a price-to-earnings (P/E) ratio of 124.5x. This suggests investors expect higher future growth.

Growth & Financials

Daxor Corporation (DXR) reported $0.9M in revenue for fiscal year 2024. This represents a 32% decrease from $1.3M in 2011.

Daxor Corporation (DXR) saw revenue decline by 93.8% over the past year.

Yes, Daxor Corporation (DXR) is profitable, generating $3.5M in net income for fiscal year 2024 (25.2% net margin).

Dividend & Returns

Daxor Corporation (DXR) has a return on equity (ROE) of 1.5%. This is below average, suggesting room for improvement.

Daxor Corporation (DXR) had negative free cash flow of $4.7M in fiscal year 2024, likely due to heavy capital investments.